Sugi Predict

Sugi Predict / Compounds / SCHEMBL782295

SCHEMBL782295

SCHEMBL782295

CCS(=O)(=O)Nc1cncc(-c2cc3c(cc2F)oc(=O)n3C)c1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 3/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ PKM P14618 7/20 0.41
▸ LMNA P02545 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ PGR P06401 1/20 0.39
▸ TP53 P04637 1/20 0.38
▸ GFER P55789 1/20 0.38
▸ BRD4 O60885 3/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ FGFR1 P11362 1/20 0.37
▸ BRPF1 P55201 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL805384 0.89 MEN1 (0.43) CYP11B2MEN1KMT2APKMLMNA
SCHEMBL782548 0.82 CYP11B2 (0.48) CYP11B2MEN1KMT2APKMLMNA
SCHEMBL783485 0.77 CYP11B2 (0.43) CYP11B2MEN1KMT2APKMLMNA
SCHEMBL783403 0.75 PTPN5 (0.44) CYP11B2MEN1KMT2APKMLMNA
SCHEMBL783473 0.74 CYP11B2 (0.54) CYP11B2MEN1KMT2APKM
SCHEMBL805366 0.73 CYP11B2 (0.49) CYP11B2MEN1KMT2APKMLMNA
SCHEMBL782798 0.71 CYP11B2 (0.43) CYP11B2BRD4BRPF1
SCHEMBL10233229 0.70 PDE10A (0.43) CYP11B2SMN1; SMN2
SCHEMBL782715 0.69 CYP11B2 (0.53) CYP11B2MEN1KMT2APKMLMNA
SCHEMBL805385 0.68 GPR55 (0.46) CYP11B2MEN1KMT2APKMHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430018-B1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS NOVARTIS AG (CH) 2013-07-03 — — EP disclosed
EP-2430018-B1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS NOVARTIS AG (CH) 2013-07-03 — — EP disclosed
US-8455522-B2 Benzoxazolone derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2013-06-04 — — US disclosed
US-8455522-B2 Benzoxazolone derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2013-06-04 — — US disclosed
US-8455522-B2 Benzoxazolone derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2013-06-04 — — US disclosed
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 — — US disclosed
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 — — US disclosed
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS CYP11B2, CYP11B1, CYP21A2 CYP11B2 1/4885MEN1 2285/4885KMT2A 3420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.